Global Angioedema Market Size, Share & Trends Analysis Report By Type (Hereditary Angioedema, Acquired Angioedema, Drug-Induced Angioedema), By Treatment (C1-Inhibitor Concentrates, Kallikrein Inhibitors, Bradykinin B2 Receptor Antagonists), By Formulation (Plasma-Derived, Recombinant, Oral, Subcutaneous, Intravenous), By Disease Severity (Mild, Moderate, Severe), By Route of Administration (Intravenous, Subcutaneous, Oral), By End-User (Hospitals & Clinics, Specialized Treatment Centers, Ambulatory Care Facilities, Home Healthcare), and By Region (North America, Europe, APAC, Middle East & Africa, LATAM) - Forecasts, 2026-2034

Table of Contents

1. Introduction
   1.1. Market Introduction
   1.2. Research Methodology
   1.3. Estimation Methodology
   1.4. Angioedema Treatment Ecosystem Overview
   1.5. Market Classification & Scope
   1.6. Geographic Scope
   1.7. Study Years
2. Market Dynamics
   2.1. Drivers: Improved HAE Diagnosis, Therapeutic Innovation, Expanding Treatment Access
   2.2. Restraints: High Drug Development Costs, Regulatory Complexity, Limited Patient Population
   2.3. Opportunities: Gene Therapy, RNA-Based Therapeutics, Oral Prophylactic Treatments
3. Market Segmentation (2025–2034)
   3.1. By Type
   3.2. By Treatment
   3.3. By Formulation
   3.4. By Disease Severity
   3.5. By Route of Administration
   3.6. By End-User
   3.7. By Region
4. Regional Overview
   4.1. North America
   4.2. Europe
   4.3. Asia Pacific
   4.4. Middle East & Africa
   4.5. Latin America
5. Competitive Analysis
   5.1. Market Share Analysis
   5.2. Product Portfolio & Pipeline Benchmarking
   5.3. Technology & Innovation Positioning
   5.4. Strategic Collaborations, Licensing & Acquisitions
6. Technology & Innovation Trends
   6.1. RNA-Targeted Therapeutics
   6.2. Gene Therapy for Hereditary Angioedema
   6.3. Oral Kallikrein Inhibitors & Self-Administration Technologies
   6.4. Patient-Centric Disease Management & Digital Monitoring
7. Regulatory Landscape
   7.1. FDA Orphan Drug & Rare Disease Programs
   7.2. EMA Regulatory Framework for Hereditary Angioedema
   7.3. Global Reimbursement & Market Access Policies
   7.4. Clinical Trial & Drug Approval Landscape
8. Market Research Findings & Conclusion
9. Disclaimer